News movingPharmaceuticals, Biotechnology & Life Sciences
United Kingdom
Pharmaceuticals, Biotechnology & Life Sciences▲
GSK Partners With Chai Discovery on AI Protein Design for Drug Discovery
GSK announced a new collaboration with Chai Discovery to apply AI-driven protein design across its drug discovery pipeline. The partnership gives GSK access to Chai Discovery's protein folding and design models focused on early stage R&D, and internal GSK evaluations reported hits against all tested targets when using those AI tools in preclinical research. The company operates as a global pharmaceutical group focused on vaccines, specialty medicines, and general treatments, with a market value of about £70.1 billion, so any impact from the collaboration will sit within a large and diversified drug portfolio. The deal is a concrete test of GSK's AI-led R&D pillar rather than a side bet, though relying more on external AI partners adds execution risk on top of patent cliffs and pressure in General Medicines that analysts already flag. Simply Wall St's analysis points to a £21.73 fair value for GSK.
GSK.LSE · Technology · Positive GSK's collaboration with Chai Discovery gives it AI protein design tools that reportedly hit all tested targets in preclinical research, advancing its AI-led R&D pipeline.
Chai Discovery · Demand · Positive Chai Discovery's protein folding and design models are being adopted by GSK across its drug discovery pipeline, a concrete partnership for its AI platform.
Moderna Fair Value Estimate Rises to US$122.67 on Cancer Vaccine Analyst Revisions
Moderna's fair value estimate has been lifted from US$119.56 to US$122.67 per share, according to updated modelling tied to analyst revisions on its intismeran cancer vaccine program. The change follows Phase 3 INTerpath-001 melanoma data that prompted target lifts or upgrades from BofA, Goldman Sachs, UBS, Barclays, RBC Capital and Morgan Stanley, with BofA setting a US$200 target and a Neutral rating and calling the readout a watershed moment for Moderna. William Blair moved to Outperform and Wolfe Research called the melanoma result de-risking for the broader intismeran platform, while RBC Capital described the data as a massive scientific breakthrough. On the bearish side, Citi and Rothschild & Co Redburn moved to Sell even as they raised targets to US$80 and US$81 respectively, citing questions on oncology revenue expectations and limited disclosure around efficacy metrics such as hazard ratios. The updated model also shifted the revenue growth assumption from 26.74% to 26.75%, the net profit margin from 17.25% to 17.20%, the future P/E from 80.90x to 83.10x, and the discount rate from 7.50% to 7.46%.
MRNA · Capital · Positive Fair value estimate raised to US$122.67 and multiple analyst price-target increases/upgrades followed the data readout.
MRNA · Technology · Positive Phase 3 INTerpath-001 melanoma data for the intismeran cancer vaccine prompted analyst target lifts and upgrades, de-risking the platform.
Haisco Elects Wang Junmin as Chairman and Appoints Yan Pangke as General Manager
Haisco announced that the first meeting of the company's sixth board of directors elected Wang Junmin as chairman. The meeting also appointed Yan Pangke as general manager, Wang Meng as deputy general manager and board secretary, Duan Peng as chief financial officer, and Guo Yan as securities affairs representative.
002653.CS · · Neutral Board elects Wang Junmin as chairman and appoints Yan Pangke as general manager; routine corporate governance changes with no clear operational or financial driver.
Haixin Co.'s largest shareholder Ningrui Investment plans to publicly solicit transfer of 10% stake
Haixin Co. announced that its largest shareholder Ningrui Investment plans to transfer 121 million unrestricted tradable shares, representing 10% of the company's total share capital, through public solicitation of transferees. The announcement shows that upon completion of this transfer, it may lead to a change in the company's largest shareholder.
600851.CG · Capital · Neutral Largest shareholder Ningrui Investment plans to transfer 10% of Haixin's shares via public solicitation, potentially changing the largest shareholder.
Hunan Ningrui Investment Partnership · Capital · Neutral Ningrui Investment, Haixin's largest shareholder, plans to publicly solicit transfer of its 10% stake, potentially ending its position as largest shareholder.
Baili Tianheng's Izabren Combined with Radiotherapy for Head and Neck Squamous Cell Carcinoma Clinical Trial Approved by NMPA
Baili Tianheng announced on October 11 that the company recently received the official approval of the Drug Clinical Trial Approval Notice from the National Medical Products Administration. Its self-developed, first-in-class drug Izabren (luncombe izabren, BL-B01D1/iza-bren) combined with radiotherapy for the treatment of locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved for clinical trials. The announcement stated that Izabren is the world's first and only approved EGFR×HER3 bispecific antibody-drug conjugate, and has currently initiated more than 45 clinical trials for multiple tumor types in China and the United States, including 20 Phase III clinical studies (including Phase II/III). Izabren has 9 indications included in the National Medical Products Administration's Center for Drug Evaluation breakthrough therapy designation list, 2 indications included in the priority review designation list, and some indications have also received marketing approval from the National Medical Products Administration. In mid-2026, Baili Tianheng achieved revenue of 0.0 yuan and a net loss attributable to the parent company of 1.637 billion yuan.
688506.CG · Technology · Positive NMPA approved clinical trial of Baili Tianheng's first-in-class Izabren combined with radiotherapy for head and neck squamous cell carcinoma.
Baili Tianheng's Yizekang Combined with Radiotherapy for Head and Neck Squamous Cell Carcinoma Receives Clinical Trial Approval
Baili Tianheng announced that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial of its self-developed, world-first bispecific antibody drug conjugate Yizekang, also known as luncoitab, in combination with radiotherapy for locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved. To date, the drug has initiated more than 45 clinical trials in China and the United States, including 20 Phase III clinical studies, and 9 indications have been included in the breakthrough therapy designation list by the Center for Drug Evaluation.
688506.CG · Regulation · Positive Baili Tianheng received NMPA clinical trial approval for Yizekang combined with radiotherapy in head and neck squamous cell carcinoma.
Haixin Co.'s largest shareholder Ningrui Investment plans to transfer 10% stake via public solicitation
Haixin Co. announced on October 11 that its largest shareholder, Hunan Ningrui Investment Partnership, and its concert party Hunan Caixin Economic Investment Co., Ltd. together hold 14.98% of the company's equity. Ningrui Investment holds 142 million shares, accounting for 11.73% of total share capital, while Caixin Economic Investment holds 39.29 million shares, accounting for 3.25%. Ningrui Investment plans to transfer 121 million unrestricted tradable shares, representing 10% of the company's total share capital, through public solicitation of a transferee. This matter may lead to a change in the company's largest shareholder. The public solicitation transfer still needs approval from the state-owned assets supervision and administration authority or other competent institutions before it can be implemented. Whether approval can be obtained and the timing of approval remain uncertain, and the transferee also remains uncertain before completion of the public solicitation transfer procedures. Specific information such as the timing of the public solicitation and transferee qualification requirements will be disclosed by the company later. In the first half of 2026, Haixin Co. achieved revenue of 312 million yuan and net profit attributable to the parent company of 129 million yuan.
600851.CG · Capital · Neutral Largest shareholder plans to transfer 10% stake via public solicitation, potentially changing the largest shareholder, but approval and transferee remain uncertain.
Hunan Ningrui Investment Partnership · Capital · Neutral Ningrui Investment is the seller transferring 121 million shares (10% stake) through public solicitation, with outcome uncertain.
Hunan Caixin Economic Investment · Capital · Neutral Concert party of the largest shareholder holding 3.25%; its stake is context for the planned 10% transfer, no independent development.
Harbin Pharmaceutical Group President Lu Chuanyou Detained; Company Says Operations Not Significantly Affected
Harbin Pharmaceutical Group announced on October 11 that director and president Lu Chuanyou recently received a case filing notice and a detention notice from the relevant supervisory committee. The company said it has made proper arrangements for related work, the chairman, other directors and senior management are performing their duties normally, and the board of directors is operating normally. The announced matter will not have a significant impact on the company's production, operation and management. In the first half of 2026, Harbin Pharmaceutical Group achieved revenue of 8.296 billion yuan and net profit attributable to the parent of 410 million yuan.
600664.CG · Regulation · Negative Director and president Lu Chuanyou was detained by a supervisory committee, a legal/regulatory action against the company's leadership.
Harbin Pharmaceutical Director and President Lu Chuanyou Placed on File and Subject to Detention
Harbin Pharmaceutical announced on the evening of October 11 that the company recently received a Notice of Case Filing and a Notice of Detention from the relevant supervisory committee regarding company director and president Lu Chuanyou. According to an announcement disclosed by the company at the end of August, the 2026 interim results briefing scheduled for September 10, 2026, still included director and president Lu Chuanyou among the participants. Lu Chuanyou previously served as chief engineer, executive deputy factory director, factory director, and party secretary of Harbin Pharmaceutical Group No. 6 Pharmaceutical Factory, party secretary, chairman, and general manager of Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd., and deputy general manager of Harbin Pharmaceutical Group Co., Ltd. Since 2023, he has served as president and member of the strategy committee of Harbin Pharmaceutical Group Co., Ltd. Harbin Pharmaceutical stated that the company has a sound organizational structure and a standardized governance system, has made proper arrangements for related work, and that the chairman, other directors, and other senior management are performing their duties normally. The board of directors is operating normally, production and operations are normal, and the announced matter will not have a material impact on the company's production, operations, or management. The company's 2026 interim report showed that first-half operating revenue reached 8.296 billion yuan, up 2.10 percent year on year; net profit attributable to shareholders of the listed company reached 410 million yuan, up 57.99 percent year on year; and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses reached 355 million yuan, up 45.39 percent year on year.
600664.CG · Regulation · Negative Director and president Lu Chuanyou placed on file and subject to detention by supervisory authorities, a legal/regulatory action against a top executive.
Harbin Pharmaceutical Group Director and President Lu Chuanyou Placed on File and Subject to Detention
Harbin Pharmaceutical Group announced that the company recently received a Notice of Filing and a Notice of Detention from the relevant supervisory committee regarding company director and president Lu Chuanyou. The company stated that it has made proper arrangements for related work, and that the chairman, other directors, and other senior management are all performing their duties normally, with the board of directors operating as usual.
600664.CG · Regulation · Negative Director and president Lu Chuanyou placed on file and subject to detention by supervisory committee, a legal/regulatory action against a top executive.
Harbin Pharmaceutical's 64-year-old president Lu Chuanyou placed under investigation and detention, earned 2.9668 million yuan last year
Harbin Pharmaceutical announced on October 11 that the company recently received a case filing notice and a detention notice from the relevant supervisory committee regarding its director and president Lu Chuanyou. Harbin Pharmaceutical said it has made proper arrangements for related work, and that the chairman, other directors, and other senior managers are all performing their duties normally. The board of directors is operating normally, and production and operations are normal. The matters in the announcement will not have a material impact on the company's production, operations, or management. According to Harbin Pharmaceutical's 2025 annual report, Lu Chuanyou is 64 years old. He previously served as chief engineer, executive deputy factory director, factory director, and party secretary of Harbin Pharmaceutical Group No. 6 Pharmaceutical Factory, party secretary, chairman, and general manager of Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd., and vice president and senior advisor of the company. He currently serves as a member of the company's party committee, a director of the 10th board of directors, a member of the board's strategy and sustainable development committee, and president. In 2025, he received a salary of 2.9668 million yuan. Harbin Pharmaceutical focuses on the pharmaceutical and health industry, mainly engaged in pharmaceutical research and development, manufacturing, wholesale, and retail. In the first half of this year, the company achieved operating revenue of 8.296 billion yuan, an increase of 2.10 percent year on year. Net profit attributable to shareholders of the listed company was 410 million yuan, an increase of 57.99 percent year on year. Net profit attributable to shareholders of the listed company after deducting non-recurring items was 355 million yuan, an increase of 45.39 percent year on year. Basic earnings per share were 0.1629 yuan.
600664.CG · Regulation · Negative President and director Lu Chuanyou placed under investigation and detained by supervisory committee, a legal/regulatory action against a top executive.
Haisco Plans to Provide Up to 165 Million Yuan Loan to Controlling Subsidiary Haisijieyin
Haisco announced on October 11 that it plans to provide financial assistance in the form of a loan using its own funds to its controlling subsidiary Haisijieyin, with the amount not exceeding 165 million yuan. Haisijieyin's minority shareholder Hailikesi will provide financial assistance under the same conditions in proportion to its capital contribution, with the amount not exceeding 18.97 million yuan. The annualized interest rate of the loan is 3.05 percent, and the loan facility is valid for five years. Haisijieyin needs to draw down the funds in installments according to its capital usage plan, and any single loan must be fully repaid by the end of the five-year period. This financial assistance is intended to promote the business development of Haisijieyin and supplement its working capital, and will not affect the company's normal business operations. In the first half of 2026, Haisco achieved revenue of 3.096 billion yuan and net profit attributable to the parent company of 851 million yuan.
002653.CS · Capital · Positive Haisco provides a 165 million yuan loan to its controlling subsidiary Haisijieyin to supplement working capital and support business development.
Helix (Chengdu) Pharmaceutical Technology Co., Ltd. · Capital · Positive Haisijieyin receives up to 165 million yuan in financial assistance from parent Haisco, supplementing its working capital.
Hybribio's Wholly-Owned Subsidiary Obtains Medical Device Registration Certificate for Vaginal Microorganism Nucleic Acid Detection Kit
Hybribio announced on October 11 that its wholly-owned subsidiary, Chaozhou Hybribio Biochemistry Co., Ltd., has recently obtained the Medical Device Registration Certificate of the People's Republic of China for in vitro diagnostic reagents issued by the National Medical Products Administration. The registered product is a vaginal microorganism nucleic acid detection kit using PCR-fluorescent probe method, valid from October 9, 2026 to October 8, 2031, primarily for the in vitro qualitative detection of nucleic acids of Trichomonas vaginalis, Gardnerella vaginalis, and Candida albicans in vaginal secretions. The company stated that obtaining this registration certificate will further improve its product portfolio for reproductive tract infection testing, meet diversified market demand, and support its goal of becoming a leading enterprise in nucleic acid molecular diagnostics. The announcement also cautioned that actual sales and profit contribution of the approved product are subject to factors such as market promotion effectiveness and actual demand, and remain uncertain; the company is currently unable to predict the impact on its future operating results. In the interim period of 2026, Hybribio achieved revenue of 300 million yuan and net profit attributable to the parent company of 31.26 million yuan.
Harbin Pharmaceutical Group Director and President Lu Chuanyou Placed on File for Investigation and Subject to Detention
Harbin Pharmaceutical Group announced that the company recently received a Notice of Case Filing and a Notice of Detention from the relevant supervisory committee regarding company director and president Lu Chuanyou. The company stated that it has made proper arrangements for related work, and that the chairman, other directors, and other senior management are all performing their duties normally, with the board of directors operating as usual.
600664.CG · Regulation · Negative Director and president Lu Chuanyou placed on file for investigation and subject to detention by supervisory authorities.
Haixin Shares' largest shareholder Ningrui Investment plans public solicitation to transfer part of its stake, possibly leading to a change in the largest shareholder
Haixin Shares announced on October 11 that its largest shareholder, Hunan Ningrui Investment Partnership, and its concert party, Hunan Caixin Economic Investment Co., Ltd., together hold 14.98% of the company's equity. Ningrui Investment plans to transfer part of the company's shares through public solicitation of transferees. This matter may lead to a change in the company's largest shareholder.
600851.CG · Capital · Neutral Largest shareholder Ningrui Investment plans a public solicitation to transfer part of its stake, possibly changing the largest shareholder.
Hunan Ningrui Investment Partnership · Capital · Neutral Ningrui Investment is the largest shareholder planning to transfer part of its Haixin Shares stake via public solicitation.
Hunan Caixin Economic Investment · Capital · Neutral Caixin Economic Investment is a concert party of Ningrui Investment, which plans the stake transfer.
Jinghua Pharmaceutical's Ji Desheng Snake Tablet Gains Clinical Trial Approval for New Shingles Indication
Jinghua Pharmaceutical announced on October 11 that it recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial application for its Ji Desheng Snake Tablet to add a new indication for shingles, specifically the liver-gallbladder damp-heat syndrome, has been approved. Ji Desheng Snake Tablet is a marketed traditional Chinese medicine product of the company, with current approved indications being clearing heat and detoxifying, reducing swelling and relieving pain, for use in venomous snake and insect bites.
002349.CS · Technology · Positive Ji Desheng Snake Tablet received NMPA clinical trial approval to add a new shingles indication, an R&D/product development for the company.
Harbin Pharmaceutical Group Director and President Lu Chuanyou Placed Under Detention
Harbin Pharmaceutical Group announced on October 11 that the company recently received a case filing notice and a detention notice from the relevant supervisory committee regarding Lu Chuanyou, a director and president of the company. The company stated that it has made proper arrangements for related work, and that the chairman, other directors, and other senior management are performing their duties normally, with the board operating normally and production and operations proceeding as usual. The announcement said the above matter will not have a significant impact on the company's production, operations, or management.
600664.CG · Regulation · Negative Director and president Lu Chuanyou placed under detention by a supervisory committee, a legal/regulatory action against the company's leadership.
Jinghua Pharmaceutical's Ji Desheng Sheyao Tablets Gain Clinical Trial Approval for New Shingles Indication
Jinghua Pharmaceutical announced on October 11 that it recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving clinical trials for Ji Desheng Sheyao Tablets to add a new indication for shingles, specifically the liver-gallbladder damp-heat syndrome. The application was accepted on July 17, 2026, and the review conclusion agreed to conduct the relevant clinical trials, with the approval date being October 8, 2026. Ji Desheng Sheyao Tablets are already on the market, with current approved functions of clearing heat, detoxifying, reducing swelling, and relieving pain, used for venomous snake and insect bites. The clinical trials for this new indication will proceed with Phase II and Phase III trials according to the general principles of drug development to verify its clinical value. The company stated that this approval will not have a significant impact on current operating performance, but drug development is characterized by high investment, long cycles, and high risk, and future market competition and research outcomes remain uncertain. In the first half of 2026, Jinghua Pharmaceutical achieved revenue of 755 million yuan and net profit attributable to the parent company of 136 million yuan.
002349.CS · Technology · Positive Received NMPA clinical trial approval to add a new shingles indication for Ji Desheng Sheyao Tablets, advancing its R&D pipeline.
Merck's Remigromig Meets Primary Endpoint in Pivotal BRUNELLO DME Trial
Merck announced that remigromig, an investigational tri-specific antibody that activates the Wnt pathway, met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema, with both dose arms demonstrating non-inferiority in mean change from baseline in best corrected visual acuity at one year versus monthly 0.5mg ranibizumab. Mean BCVA gains at Year 1 were +9.1 letters with remigromig 0.5 mg and +8.7 letters with remigromig 0.8 mg, compared with +11.8 letters with ranibizumab, and no secondary endpoints demonstrated superiority to ranibizumab. The company said remigromig is the first biologic with a novel mechanism of action to demonstrate non-inferior visual acuity compared with anti-VEGF therapy in a pivotal DME trial, and the first new mechanism of action in more than 20 years to do so. Adverse events related to proliferative diabetic retinopathy occurred more frequently with remigromig than with ranibizumab, at 6.7% and 6.1% for the 0.5 mg and 0.8 mg arms versus 0.9%, and treatment discontinuations due to adverse events were also higher, at 4.9% and 4.5% versus 0.9%. The results, presented at the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans, will be discussed with regulatory authorities, and remigromig is also being evaluated in the ongoing pivotal Phase 2b/3 BAROLO study in DME and a Phase 2 proof-of-concept study in NVAMD and RVO.
MRK.XETRA · Technology · Positive Remigromig met the primary endpoint in the pivotal BRUNELLO DME trial, a positive R&D/clinical result for Merck KGaA.
Roche's vamikibart shows one-year vision gains in uveitic macular edema as FDA accepts BLA
Roche announced new one-year data from the Phase III MEERKAT and SANDCAT studies showing that investigational vamikibart sustained improvements in vision and reductions in macular thickness in adults with uveitic macular edema at 52 weeks compared with a sham procedure. The results were presented at the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans. The FDA has accepted Roche's Biologics License Application for vamikibart for the treatment of UME, with an approval decision expected by July 2027; if approved, vamikibart would be the first non-steroid targeted treatment for UME. Regulatory submissions have also been filed and accepted in the European Union, China and Japan. In both trials, a numerically higher proportion of vamikibart-treated patients achieved vision gains than those on sham treatment on the primary endpoint, and key secondary endpoints showed sustained improvements in best corrected visual acuity and central subfield thickness. Vamikibart was well tolerated with a low incidence of treatment-related ocular adverse events and intraocular inflammation events, and approximately two-thirds of eligible patients required no retreatment after 16 weeks.
Schneider Electric to buy PTC for $22.6 billion as deal wave sweeps sectors
Schneider Electric SE agreed to acquire U.S.-based engineering software developer PTC Inc. for $22.6 billion, or €20.1 billion, paying $205 per share in an all-cash deal. The transaction was among a string of major deals reported across sectors this week. Viatris said it will acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, while CD&R and McKesson agreed to acquire Option Care Health for $32.05 per share, valuing it at approximately $5.8 billion including debt, sending its shares up 34% in early trading Tuesday. Energy Transfer agreed to acquire Vaquero Midstream in a $2.625 billion deal consisting of $1.95 billion in cash and about 33.3 million newly issued Energy Transfer common units, and Cenovus Energy agreed to acquire Athabasca Oil in a cash-and-stock deal valued at about C$5.7 billion, a 14% premium to Athabasca's 20-day volume-weighted average trading price. Canadian utilities Emera and Canadian Utilities agreed to an all-stock merger worth C$14.3 billion, or US$10 billion, creating a combined company with a C$72 billion enterprise value and a regulated rate base of C$45 billion serving roughly 6 million customers. Separately, TKO LLC proposed to acquire Service Properties Trust's entire hospitality portfolio for $2.0 billion, and CCC Intelligent Solutions soared 13% in after-hours trading on a report that GTCR and Elliott Investment Management are in advanced discussions to purchase the car-insurance software firm.
CCC · Capital · Positive CCC Intelligent Solutions soared 13% after-hours on a report that GTCR and Elliott are in advanced talks to acquire the firm.
CVE · Capital · Positive Cenovus Energy agreed to acquire Athabasca Oil in a cash-and-stock deal valued at about C$5.7 billion.
EMA · Capital · Positive Emera agreed to an all-stock merger with Canadian Utilities worth C$14.3 billion, creating a combined utility with a C$72 billion enterprise value.
ET · Capital · Positive Energy Transfer agreed to acquire Vaquero Midstream for $2.625 billion in cash and newly issued common units.
MCK · Capital · Positive McKesson, with CD&R, agreed to acquire Option Care Health for $32.05 per share, valuing it at about $5.8 billion including debt.
OPCH · Capital · Positive CD&R and McKesson agreed to acquire Option Care Health for $32.05 per share, a takeover deal that lifts its shares.
Natera Wins FDA Breakthrough Device Designation for Multi-Cancer Blood Test
The US Food and Drug Administration granted Breakthrough Device designation to Natera's multi cancer early detection blood test, a move that reshapes how investors frame the company's diagnostics pipeline. The designation follows a strong run in Natera's share price, with a 30-day return of 21.31%, a 90-day move of 48.44%, a year-to-date gain of 75.10%, and a 1-year total shareholder return of 136.73%. The stock's latest close of $400.71 sits above the most followed fair value estimate of $355.93, which implies the shares are 13% overvalued under a 7.5% discount rate. By contrast, the Simply Wall St discounted cash flow model estimates a future cash flow value of $599.47, suggesting the shares trade about 33% below that level. Natera's investment in new product launches such as Fetal Focus NIPT, Signatera Genome, and AI-based biomarkers, along with its R&D pipeline, positions it to capture growth from long-term trends in personalized medicine and early detection, though tighter reimbursement rules or sustained high R&D spending could pressure profitability.
NTRA · Regulation · Positive FDA granted Breakthrough Device designation to Natera's multi-cancer early detection blood test, a regulatory milestone for its diagnostics pipeline.
AstraZeneca Launches AI Biologics Discovery Tie-Up With Carterra
AstraZeneca has launched a new AI-driven biologics discovery collaboration with Carterra, announced ahead of trading on 9 October 2026. The partnership links AstraZeneca's AI models with Carterra's high-throughput biosensor instruments to create autonomous, lab-in-the-loop discovery workflows. The project focuses on large molecule biologics, aiming to shorten experimental decision cycles and scale up antibody and protein engineering campaigns. AstraZeneca, which operates at a £186.1 billion market cap scale, is betting that the tie-up supports the premise that heavier spending on technologies like AI will translate into faster, more targeted drug launches and stronger earnings power. The unresolved question is whether such AI collaborations can offset pressure from patent expiries, price controls and high core R&D spend, especially as competitors like Pfizer and Merck also wire AI into their discovery lines.
AZN.LSE · Technology · Positive AstraZeneca launched an AI-driven biologics discovery collaboration with Carterra to speed antibody and protein engineering.
Carterra · Demand · Positive Carterra's biosensor instruments are being adopted in AstraZeneca's AI biologics discovery partnership.
vTv Therapeutics Presents Data on Hypoglycemia Burden in Type 1 Diabetes at Breakthrough T1D Congress
vTv Therapeutics announced that Chief Medical Officer Thomas Strack presented new research on hypoglycemia-related burdens among adults with type 1 diabetes using automated insulin delivery systems at the inaugural Breakthrough T1D Clinical & Research Congress in Philadelphia. The study, commissioned by vTv and conducted by dQ&A Market Research, surveyed 674 adults with type 1 diabetes, of whom 429 were using automated insulin delivery systems. Among those AID users, 24% reported frequent Level 2 hypoglycemia, 12% reported a Level 3 event in the past 12 months, and 17% reported impaired awareness of hypoglycemia. After accounting for overlap across segments and weighting for A1C, approximately 54% of adults with type 1 diabetes using an AID system were estimated to experience at least one of four hypoglycemia-related burden dimensions. The research supports vTv's cadisegliatin, a potential first-in-class oral liver-selective glucokinase activator being evaluated as an adjunctive therapy to insulin for type 1 diabetes, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration.
VTVT · Technology · Positive New research on hypoglycemia burden in AID users supports vTv's cadisegliatin, a first-in-class oral glucokinase activator with FDA Breakthrough Therapy designation for type 1 diabetes.
LB Pharmaceuticals Presents Preclinical Data on LB-102 Mechanism at ECNP Congress
LB Pharmaceuticals announced the presentation of four posters at the 39th European College of Neuropsychopharmacology Congress in Munich, Germany, running October 10-13, 2026. The posters cover new preclinical data on LB-102's differentiated mechanism of action, the pivotal Phase 3 program in schizophrenia known as NOVA-2 and NOVA-3, the ongoing late-stage Phase 2 ILLUMINATE-1 trial in bipolar depression, and a previously reported analysis of LB-102's impact on cognitive performance from the Phase 2 NOVA-1 trial in schizophrenia. The preclinical data showed that LB-102 can modulate dopamine signaling through engagement of pre-synaptic D2 autoreceptors, increasing dopamine neurotransmission, which the company said supports a potential mechanism for addressing the hypodopaminergic state associated with anhedonia and diminished motivation in depression. A post hoc analysis of the Phase 2 NOVA-1 trial found that the dose-dependent, statistically significant improvements in cognitive performance were primarily a direct effect of LB-102 rather than an indirect consequence of the drug's effect on total schizophrenia symptoms. LB-102 is a novel, once-daily, orally administered investigational small molecule engineered as a modification to amisulpride, and the company believes it has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
LBRX · Technology · Positive Presented preclinical data on LB-102's differentiated mechanism and Phase 2/3 trial results supporting its antipsychotic and cognitive effects.
AbbVie Wins Two FDA Breakthrough Therapy Tags for Telisotuzumab Adizutecan
AbbVie received two FDA Breakthrough Therapy Designations for its experimental cancer drug telisotuzumab adizutecan in colorectal cancer and non small cell lung cancer. The designations apply to biomarker defined patient groups in those two large solid tumor indications, and they mark the first Breakthrough Therapy status for telisotuzumab adizutecan, which sits in AbbVie's antibody drug conjugate pipeline. Colorectal cancer and non small cell lung cancer together affect more than four million people worldwide each year, and the focus on biomarker defined groups, including c Met protein expressing NSCLC, points to narrower patient pools but potentially higher value treatment settings. The designations support the view that AbbVie needs its pipeline to replace aging blockbusters such as Humira and Imbruvica, with telisotuzumab adizutecan complementing oncology assets like etentamig. The next signpost is how the ongoing Phase 3 and Phase 2/3 telisotuzumab adizutecan studies progress and when AbbVie moves toward regulatory filings in colorectal cancer and non small cell lung cancer, building on the first in human M21 404 data.
ABBV · Technology · Positive FDA granted two Breakthrough Therapy Designations for AbbVie's experimental telisotuzumab adizutecan in colorectal and NSCLC, advancing its ADC pipeline.
3SBio Signs MindRank AI Deal to Commercialize Oral GLP-1 Obesity Drug MDR-001
3SBio subsidiaries Zhejiang Sunshine Mandi and Zhejiang Wansheng have signed an agreement with MindRank AI to commercialize MDR-001, an oral GLP-1 candidate in Phase 3 obesity trials. The deal lands as 3SBio shares trade at HK$15.07, with a 1-year total shareholder return down 45.58 percent, a 30-day share price return down 6.69 percent and a year-to-date share price return down 38.69 percent, even as the 3-year total shareholder return is up more than 2x. On valuation, 3SBio trades at a P/E of 3.9x against a Hong Kong Biotechs industry average of 17.3x and a peer group average of 36.2x, with an estimated fair P/E of 8.2x. A discounted cash flow model puts 3SBio's estimated future cash flow value at HK$33.62 versus the current HK$15.07 share price. Recent declines in revenue and net income, combined with the weak 1-year return, could pressure sentiment if MDR-001 progress disappoints.
1530.HK · Demand · Positive 3SBio subsidiaries signed a deal with MindRank AI to commercialize the Phase 3 oral GLP-1 obesity candidate MDR-001, expanding its obesity drug pipeline.
MindRank AI Ltd · Demand · Positive MindRank AI signed the agreement with 3SBio to commercialize its oral GLP-1 candidate MDR-001.
603010.CG · Demand · Positive Zhejiang Wansheng is named as a 3SBio subsidiary signing the agreement to commercialize MDR-001.
Zhejiang Sansheng Wandi Pharmaceutical · Demand · Positive Zhejiang Sunshine Mandi is named as a 3SBio subsidiary signing the agreement to commercialize MDR-001.
Akeso Doses First Patient in Phase III Perioperative Cadonilimab Colon Cancer Study
Akeso, Inc. announced that the first patient has been dosed in a Phase III clinical study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoadjuvant/adjuvant perioperative treatment of resectable microsatellite instability-high or mismatch repair-deficient colon cancer. The trial, designated COMPASSION-40/AK104-313, marks a significant new indication for cadonilimab beyond gastric, lung, and cervical cancers, and is the 13th Phase III or registrational study of the therapy conducted globally. Colorectal cancer is among the malignancies with the highest incidence and mortality worldwide, and patients with MSI-H/dMMR colon cancer derive limited benefit from conventional perioperative chemotherapy, with pathological response rates of only approximately 7%. No immunotherapy has yet been approved anywhere for the perioperative treatment of localized MSI-H/dMMR colon cancer. Supporting evidence comes from a prior Phase II study of cadonilimab monotherapy as neoadjuvant treatment in MSI-H/dMMR colorectal cancer, where data presented at the 2024 ESMO Immuno-Oncology Congress showed a pathological complete response rate of 84.6% and a major pathological response rate of 100% among patients who proceeded to surgery, with a manageable safety profile.
9926.HK · Technology · Positive First patient dosed in Phase III trial of cadonilimab for perioperative MSI-H/dMMR colon cancer, a new indication with strong prior Phase II response data.
Natera Wins FDA Breakthrough Device Designation for Multi-Cancer Blood Test
The U.S. Food and Drug Administration granted Breakthrough Device designation to Natera's blood-based multi-cancer early detection assay, sending shares of the genetic testing company up 1.7% in the morning session. The regulatory decision followed the agency's evaluation of performance data spanning 12 cancer types, assessing the assay's sensitivity, specificity, and cancer signal origin performance. The FDA Breakthrough Devices Program is designed to expedite the development and review of medical devices that diagnose or treat life-threatening conditions. Natera shares were trading at $400.22, up 2.2% from the previous close, and the stock is up 74.9% since the beginning of the year. The move comes 17 days after the stock gained 5.2% on news that Japan's Pharmaceuticals and Medical Devices Agency granted regulatory approval for its Signatera test as a companion diagnostic in muscle-invasive bladder cancer, with a commercial launch in Japan planned for the first half of 2027.
NTRA · Regulation · Positive FDA granted Breakthrough Device designation to Natera's multi-cancer early detection blood test, expediting development and review.
Pharmaron's Overseas Employee Shareholding Platform Plans to Transfer 1% Stake via Inquiry
Pharmaron announced that shareholder Pharmaron Holdings Limited plans to transfer 18.373 million shares of the company through inquiry, representing 1.00% of total share capital, with the reason being its own capital needs. The transferor is the company's overseas employee shareholding platform, with actual controller Boliang Lou. It is not a controlling shareholder of the company, but a person acting in concert with the actual controller and a shareholder holding more than 5% of shares. Its shareholders include directors and senior management of the company. The transferees are institutional investors, and the transferred shares cannot be sold within six months after the transfer. The lower limit of the inquiry transfer price shall not be less than 70% of the average stock trading price over the 20 trading days before the date of sending the subscription invitation. Huatai United Securities will determine the transfer price after the quotation based on the principles of price priority, quantity priority, and time priority. Financial data shows that in the first half of this year, the company's operating revenue was 7.595 billion yuan, up 17.92% year-on-year; net profit attributable to the parent was 750 million yuan, up 6.96% year-on-year; and non-GAAP net profit attributable to the parent was 693 million yuan, up 8.87% year-on-year. As of the close on October 9, Pharmaron fell 1.46% to 43.11 yuan per share, with a total market value of 79.21 billion yuan.
300759.CS · Capital · Negative Overseas employee shareholding platform plans to transfer 1% stake via inquiry due to its own capital needs, signaling potential selling pressure.
KingMed Diagnostics Co-releases DeepGEM 2.0, a Multimodal AI Model for Lung Cancer Pathology Genomics
On October 10, the AI-Empowered Precision Diagnosis and Treatment of Lung Cancer Summit Forum and the launch ceremony for the National Respiratory Medicine Center's Lung Cancer Precision Diagnosis and Treatment Standardization Project, hosted by the National Respiratory Medicine Center of the First Affiliated Hospital of Guangzhou Medical University and the Guangdong Provincial Chest Disease Society, and organized by KingMed Diagnostics, was held in Guangzhou. At the event, DeepGEM 2.0, a multimodal AI model for lung cancer pathology genomics jointly developed by the First Affiliated Hospital of Guangzhou Medical University and KingMed Diagnostics, was officially released. A multicenter research project involving 50 medical institutions nationwide was also launched, marking the model's formal entry into large-scale clinical validation. According to Dr. Liu Si, head of KingMed Diagnostics' artificial intelligence division, DeepGEM 2.0 analyzes routine digital pathology slide images without requiring additional sampling and can deliver results in as little as one minute. Building on the original six genes—EGFR, KRAS, ALK, ROS1, TP53, and LRP1B—it adds BRAF, ERBB2, FGFR, MET, NTRK, and RET, bringing the total to 12 genes and achieving full coverage of genes corresponding to approved targeted therapies for lung cancer in China. The model will subsequently be deployed in a lightweight form at more than 500 medical institutions. Using an approach of AI-based initial screening combined with targeted validation of specific genes, it is expected to reduce the cost of lung cancer genetic testing to the range of several hundred yuan. Zhong Nanshan, an academician of the Chinese Academy of Engineering and director of the Guangzhou National Laboratory, said that in the new AI era, scientific research must aim high while serving the people. In 2025, the First Affiliated Hospital of Guangzhou Medical University, together with KingMed Diagnostics and Tencent, released DeepGEM, a multimodal pathology genomics model capable of identifying genes from images. After nearly a year of multicenter data validation and clinical refinement, and iterative optimization using nearly 8,000 digital pathology slides from 31 provinces across China provided by KingMed Diagnostics, it has been upgraded to version 2.0. Liang Yaoming, chairman and CEO of KingMed Diagnostics, said that AI pathology technology brings new opportunities to narrow regional disparities in diagnosis and treatment and to reduce costs while improving efficiency. KingMed Diagnostics will leverage the network advantages of its nationwide intelligent medical diagnostic service platform to bring innovative pathology AI technology to primary-level healthcare.
603882.CG · Technology · Positive KingMed co-released DeepGEM 2.0, a multimodal AI model for lung cancer pathology genomics, expanding to 12 genes and entering large-scale clinical validation.
Shengnuo Bio's actual controller and subsidiary sued over bid-rigging in the seventh national drug procurement round
Shengnuo Bio announced on the evening of October 9 that its wholly owned subsidiary Shengnuo Pharmaceutical and actual controller Wen Yongjun had received an indictment issued by the People's Procuratorate of Yuhuatai District, Nanjing, Jiangsu Province. According to the prosecution opinion from the Yuhuatai branch of the Nanjing Public Security Bureau, Shengnuo Pharmaceutical is suspected of participating in bid-rigging for octreotide acetate injection in the seventh national centralized drug procurement round. Relevant personnel promised benefits, and Shengnuo Pharmaceutical actually won the bid as the fifth-ranked bidder, with illegal gains of 10.98 million yuan during the contract period. The Yuhuatai procuratorate believes that Shengnuo Pharmaceutical and Wen Yongjun colluded with other companies and individuals in submitting bid prices during the seventh national centralized drug procurement round, harming the interests of the tenderer or other bidders, with serious circumstances, violating Article 223, Paragraph 1 of the Criminal Law of the People's Republic of China. The criminal facts are clear and the evidence is reliable and sufficient, so criminal liability for the crime of bid-rigging should be pursued. Shengnuo Bio stated that Wen Yongjun is still performing his duties normally while released on bail pending trial, and the company has made a provision for the above 10.98 million yuan in illegal gains in its 2025 financial statements, which is expected to affect net profit attributable to the parent company this year or in future years. In the first half of this year, the company achieved revenue of 507 million yuan, up 50.27 percent year on year, and net profit attributable to the parent company of 135 million yuan, up 51.98 percent year on year.
688117.CG · Regulation · Negative Subsidiary and actual controller indicted for bid-rigging in the seventh national drug procurement round, with 10.98 million yuan illegal gains provisioned and potential criminal liability.
Shengnuo Bio subsidiary and actual controller prosecuted over bid-rigging in seventh national drug procurement round, with illegal gains of 10.9796 million yuan
Shengnuo Bio announced on the evening of October 9 that its wholly owned subsidiary Chengdu Shengnuo Biopharmaceutical Co., Ltd. and actual controller and chairman Wen Yongjun recently received an indictment from the People's Procuratorate of Yuhuatai District, Nanjing, Jiangsu Province, for alleged collusive bidding in the seventh national centralized drug procurement round, with illegal gains of 10.9796 million yuan. According to the prosecution opinion from the Yuhuatai branch of the Nanjing Public Security Bureau, Shengnuo Pharmaceutical is suspected of participating in bid-rigging for octreotide acetate injection in the seventh procurement round. Relevant personnel made commitments, and Shengnuo Pharmaceutical actually won the bid in fifth place, with illegal gains of 10.9796 million yuan during the contract period. Wen Yongjun was released on bail pending trial by the Yuhuatai branch on December 18, 2024, on suspicion of bid-rigging, and was again released on bail by the Yuhuatai procuratorate on December 17, 2025. He continues to perform his duties normally during the bail period. The company has already recognized a provision for the above 10.9796 million yuan in illegal gains in its 2025 financial statements. The subsequent fine amount will be determined after the case is concluded by the People's Court of Yuhuatai District, Nanjing, Jiangsu Province, and is expected to affect the company's net profit attributable to shareholders of the listed company for this year or future years. In the first half of 2026, Shengnuo Bio achieved operating revenue of 507 million yuan, up 50.27 percent year on year, and net profit attributable to shareholders of the listed company of 135 million yuan, up 51.98 percent year on year.
688117.CG · Regulation · Negative Wholly owned subsidiary and chairman indicted for bid-rigging in national drug procurement, with 10.98M yuan illegal gains and potential fines hitting net profit.
成都圣诺生物制药有限公司 · Regulation · Negative Shengnuo Pharmaceutical is the subsidiary prosecuted for collusive bidding on octreotide acetate injection in the seventh procurement round.
Jingxin Pharmaceutical Files for Hong Kong Listing a Second Time, Holding 2.385 Billion Yuan in Cash, Sparking Debate Over Fundraising Necessity
Jingxin Pharmaceutical has recently updated its H-share listing application with the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. This marks the company's second submission of listing materials to the main board of the Hong Kong Stock Exchange, following the lapse of its first filing in February 2026 after the six-month validity period expired. The Hong Kong fundraising is earmarked for four main purposes: new drug research and development, market channel expansion, industrial mergers and acquisitions and cooperation, and general working capital. However, the company has not disclosed the specific proportion of investment for each direction, nor has it disclosed details of the corresponding research and development pipeline. Financial data shows that as of the end of 2025, the company's cash-like assets totaled as much as 2.385 billion yuan, while interest-bearing liabilities in the same period were only 215 million yuan in short-term borrowings, with no long-term debt pressure. From 2023 to 2025, operating cash flow amounted to 793 million yuan, 726 million yuan, and 781 million yuan respectively. In 2025, the company implemented cash dividends of 287 million yuan and share repurchases of 609 million yuan, with the combined amount of dividends and repurchases accounting for 118.21 percent of the net profit attributable to the parent company for that year. At the same time, the company's research and development expenses have declined for three consecutive years, falling from 401 million yuan to 383 million yuan, and further dropping to 368 million yuan. The proportion of research and development investment to revenue also decreased from 10.0 percent to 9.0 percent. In the first half of 2026, research and development expenses fell 10.89 percent year-on-year, with the revenue share further declining to 8.3 percent. Revenue for the period was 1.987 billion yuan, down 1.46 percent year-on-year, and net profit attributable to the parent company was 352 million yuan, down 9.35 percent year-on-year. The prospectus discloses that the utilization rate of the company's core generic drug production lines fell from 77 percent in 2023 to 61.3 percent in the first half of 2026, while the utilization rate of traditional Chinese medicine production lines dropped from 55.6 percent to 24.9 percent. As the core asset of the company's transformation and innovation, the only approved Class 1 innovative drug, Dimdazenil, under the trade name Jingnuoning, was approved for marketing in November 2023 and included in the national medical insurance catalog in November 2024. However, this product was not independently developed but is a licensed-in variety. Jingxin Pharmaceutical obtained the development and commercialization rights in China through a licensing agreement in 2010. The fastest-progressing candidate in the research pipeline is JX2201, targeting the Lp(a) cardiovascular target, which has obtained an Investigational New Drug approval in the United States but has not yet initiated overseas clinical trials. The Phase I clinical trial in China has been completed, and Phase II dose exploration studies are currently being advanced.
002020.CS · Capital · Neutral Jingxin refiles for a Hong Kong H-share listing to raise funds for R&D, channel expansion, M&A and working capital, despite holding 2.385 billion yuan in cash and no long-term debt, sparking debate over the necessity of fundraising.
Jindike halts sales of core quadrivalent flu vaccine; full-year revenue may fall below 100 million yuan, triggering delisting risk warning
Jindike issued a risk warning announcement on the evening of October 9, saying that because the World Health Organization adjusted the recommended composition of influenza vaccines, the company will no longer sell its core product, the quadrivalent influenza vaccine, in this flu season. The newly approved trivalent influenza vaccine has no products available for sale yet, so full-year revenue may fall below 100 million yuan and the company may fail to return to profitability. If the annual report triggers the financial delisting risk warning condition, the Shanghai Stock Exchange will impose a delisting risk warning on the company's shares. According to the recommended composition for the 2026-2027 Northern Hemisphere influenza vaccines published by the World Health Organization and the Chinese National Influenza Center, the B/Yamagata lineage virus has been removed, and quadrivalent influenza vaccines containing that lineage no longer meet current seasonal vaccination demand, making trivalent influenza vaccines the main products promoted in the market. Jindike's operating revenue currently comes entirely from the quadrivalent influenza vaccine. The trivalent vaccine has just been approved and still needs to obtain a biological product batch release certificate before it can be marketed, and sales are also constrained by the progress of local government procurement and bidding. As of the announcement date, no trivalent vaccine is available for sale. The company listed on the STAR Market in 2021, with operating revenue of 318 million yuan in its first year of listing. Since then, performance has continued to deteriorate, with net profit negative for three consecutive years: a loss of 70.99 million yuan in 2023, a loss of 93.5 million yuan in 2024, and a loss widening to 178 million yuan in 2025. In the first half of 2026, revenue was 910,900 yuan, down 74.15 percent year on year, and net profit attributable to the parent company was negative 51.07 million yuan, with the loss widening 28.79 percent year on year. As of the close on October 9, Jindike traded at 19.17 yuan per share, up 5.21 percent, with a total market value of 2.362 billion yuan.
688670.CG · Regulation · Negative WHO composition change removed the B/Yamagata lineage, making Jindike's only revenue-generating quadrivalent flu vaccine unsellable and triggering a delisting risk warning.
Allist Responds to Failure of Furmonertinib Overseas Phase III Clinical Study
Allist responded to media on October 9 regarding the failure of the overseas Phase III clinical study of its core product furmonertinib, stating that the FURVENT study data require further analysis and that the company will determine subsequent development and regulatory communication plans. The company believes the FURVENT study results will not affect furmonertinib's sales in the third quarter or in the future, as current sales of the drug mainly come from the first-line treatment indication for EGFR-sensitive mutations. Allist said that at the subsequent global investigator meeting for the FURVENT study, experts believed furmonertinib met prior efficacy expectations for EGFR exon 20 insertion mutations; the chemotherapy arm's progression-free survival assessed by blinded independent central review differed substantially from investigator-assessed results, and apart from this difference, other data for furmonertinib performed well. On the same day, the National Healthcare Security Administration separately published the first batch of primary-level disease categories, including 31 DRG primary-level disease groups and 127 DIP primary-level disease categories, for local implementation reference.
688578.CG · Technology · Negative Overseas Phase III FURVENT study of core product furmonertinib failed, requiring further data analysis and uncertain regulatory path.
Hisun Pharmaceutical's Controlling Subsidiary Obtains Veterinary Drug Approval for Telmisartan for Cats
Hisun Pharmaceutical announced that its controlling subsidiary, Hisun Animal Health, recently received the veterinary drug product approval number for telmisartan oral solution for cats, approved by the Ministry of Agriculture and Rural Affairs. The approval is valid from October 8, 2026 to October 7, 2031, with a specification of 30 milliliters to 0.12 grams. The product is used to treat proteinuria caused by chronic kidney disease in cats, and will help enrich the company's pet drug product line.
600267.CG · Regulation · Positive Controlling subsidiary Hisun Animal Health received veterinary drug approval for telmisartan oral solution for cats, enriching its pet drug product line.
Shengnuo Bio subsidiary and actual controller prosecuted for bid-rigging, with illegal gains of 10.9796 million yuan
Shengnuo Bio announced on the evening of October 9 that its wholly owned subsidiary Chengdu Shengnuo Biopharmaceutical Co., Ltd. and actual controller Wen Yongjun had received an indictment from the People's Procuratorate of Yuhuatai District, Nanjing, Jiangsu Province, on suspicion of bid-rigging, with illegal gains of 10.9796 million yuan. According to the announcement, Shengnuo Pharmaceutical is suspected of participating in bid-rigging for the drug octreotide acetate injection in the seventh national volume-based procurement program. Relevant personnel promised, and Shengnuo Pharmaceutical actually won the bid as the fifth-ranked bidder, with illegal gains of 10.9796 million yuan during the contract period. Shengnuo Pharmaceutical sold 7.5107 million units of the injection, with sales amounting to 117 million yuan. Wen Yongjun was released on bail pending trial by the Yuhuatai branch on December 18, 2024, on suspicion of bid-rigging, and was again released on bail pending trial by the Yuhuatai procuratorate on December 17, 2025. He is still performing his duties normally. The procuratorate holds that this case constitutes a joint crime and a unit crime, and that Wen Yongjun, as the directly responsible person in charge, is the principal offender. However, because he surrendered voluntarily and truthfully confessed his crimes, he is considered to have turned himself in and may be given a lighter punishment. The company has already made a provision for the illegal gains of 10.9796 million yuan as an estimated liability in its 2025 financial statements. Because the amount of the fine is not yet determined, it is expected to affect the net profit attributable to shareholders of the listed company for this year or future years.
688117.CG · Regulation · Negative Wholly owned subsidiary and actual controller indicted for bid-rigging in national procurement, with illegal gains of 10.9796 million yuan and potential fines affecting net profit.
成都圣诺生物制药有限公司 · Regulation · Negative The subsidiary itself is prosecuted for bid-rigging the octreotide acetate injection in the seventh national volume-based procurement, with 10.9796 million yuan in illegal gains.
UBS Cuts PolyPeptide Group to Neutral After Samsung Biologics Tender Offer
UBS downgraded PolyPeptide Group to neutral following Samsung Biologics' all cash tender offer, shifting investor focus toward deal completion rather than further upside. PolyPeptide shares trade at CHF43.85, close to both the UBS target and Samsung's offer, after an 82.71% share price return and an 81.20% total shareholder return over one year, though the 5 year total shareholder return remains down 63.39%. The most followed narrative pegs fair value at CHF39.09, implying the stock is 12% overvalued, based on a discount rate of 4.89%. The peptide therapeutics market is expected to grow more than 15% annually with nearly 500 drugs in late stage development, but PolyPeptide could struggle to convert its Phase III exposure into sustained commercial wins if programs are delayed or terminated, pressuring revenue growth and EBITDA progression.
PPGN.SW · Capital · Neutral UBS downgraded PolyPeptide to neutral after Samsung Biologics' tender offer, with shares near the offer price and fair value seen 12% overvalued
207940.KO · Capital · Positive Samsung Biologics' all-cash tender offer for PolyPeptide is an M&A move that expands its peptide business
Vertex Pharmaceuticals Rises 1.36% as Earnings Report Nears
Vertex Pharmaceuticals shares closed up 1.36% at $510.08, outpacing the S&P 500's 0.6% gain. The drugmaker is scheduled to report earnings on November 2, 2026, with analysts projecting earnings of $4.84 per share, representing year-over-year growth of 0.83%, and revenue of $3.4 billion, up 10.43% from the year-ago period. For the full year, the Zacks Consensus Estimates call for earnings of $18.86 per share and revenue of $13.21 billion, changes of +2.5% and +10.09% respectively from last year. The Zacks Consensus EPS estimate has moved 1.03% lower within the past month, and Vertex Pharmaceuticals currently carries a Zacks Rank of #3 (Hold). The stock trades at a Forward P/E ratio of 26.69, a premium to its industry's average of 23.15, and has a PEG ratio of 1.95 versus the Medical - Biomedical and Genetics industry average of 1.7.
VRTX · Capital · Neutral Shares rose 1.36% ahead of its Nov 2 earnings report, with analyst estimates and a Zacks #3 (Hold) rank cited; no company-specific development beyond the upcoming earnings and valuation context.
United Kingdom
